Wide Ranks

MRUS

Merus N.V.

44.97

Top Statistics
Market Cap 3 B Forward PE -11.92 Revenue Growth 6.70 %
Current Ratio 8.32 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -10.76 Enterprise / Revenue 68.40 Price To Sales Trailing12 Months 85.68
Profitability
Profit Margins 0.00 % Operating Margins -613.59 %
Balance Sheet
Total Cash 632 M Total Cash Per Share 9.23 Total Debt 11 M
Total Debt To Equity 1.57 Current Ratio 8.32 Book Value Per Share 10.28
All Measures
Short Ratio 2382.00 % Message Board Id finmb_24929296 Shares Short Prior Month 8 M
Return On Equity -0.4460 City Utrecht Uuid 42321671-9233-3f73-a2ee-487472589127
Previous Close 45.87 First Trade Date Epoch Utc 1 B Book Value 10.28
Beta 1.12 Total Debt 11 M Volume 558513
Price To Book 4.38 Fifty Two Week Low 22.27 Total Cash Per Share 9.23
Total Revenue 35 M Shares Short Previous Month Date 1 B Target Median Price 86.50
Max Age 86400 Recommendation Mean 1.25 Sand P52 Week Change 0.3133
Operating Margins -613.59 % Target Mean Price 85.64 Net Income To Common -244556000
Short Percent Of Float 0.1287 Implied Shares Outstanding 68 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 707540 Average Volume10days 707540
Total Cash 632 M Next Fiscal Year End 1 B Revenue Per Share 0.5840
Held Percent Insiders 0.0203 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 45.87 Target Low Price 67.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 50.12 Open 45.87
Free Cashflow -109096128 Dividend Yield 0.00 % Return On Assets -0.2160
Time Zone Short Name EST Trailing Eps -4.03 Day Low 44.76
Address1 Uppsalalaan 17 Shares Outstanding 68 M Price Hint 2
Target High Price 111.00 Website https://www.merus.nl 52 Week Change 0.8177
Average Volume 513931 Forward Eps -3.90 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 794.40 % Is_sp_500 False
Regular Market Day High 46.01 Profit Margins 0.00 % Debt To Equity 1.57
Fifty Two Week High 61.61 Day High 46.01 Shares Short 8 M
Regular Market Open 45.87 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 68.40 Revenue Growth 6.70 % Shares Percent Shares Out 0.1279
Operating Cashflow -155524992 Currency USD Time Zone Full Name America/New_York
Market Cap 3 B Is_nasdaq_100 False Zip 3584 CT
Quote Type EQUITY Industry Biotechnology Long Name Merus N.V.
Regular Market Day Low 44.76 Held Percent Institutions 1.06 Current Price 44.97
Address2 3rd & 4th floor Enterprise To Ebitda -10.76 Financial Currency USD
Current Ratio 8.32 Industry Disp Biotechnology Number Of Analyst Opinions 14
Country Netherlands Float Shares 62 M Two Hundred Day Average 49.74
Enterprise Value 2 B Price To Sales Trailing12 Months 85.68 Forward PE -11.92
Regular Market Volume 558513 Ebitda -228456992 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Merus N.

V.

, a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.

Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.

In addition, it has collaboration agreement with Betta Pharmaceuticals Co.

Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers.

The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.